4.7 Article

Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 410, Issue 1, Pages 101-104

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/S0014-2999(00)00865-7

Keywords

oestrogen receptor modulator; oestrogen; nitric oxide (NO); blood pressure; vasopressin; enzyme regulation

Ask authors/readers for more resources

Administration of graded doses of [Arg(8)]vasopressin (0.06-0.18 mug kg(-1), i.v.) induced a dose-dependent increase in arterial blood pressure in the catecholamine-depleted (phentolamine; 10 mg kg(-1), i.p.) intact and ovariectomized female rat, with the elevation of blood pressure more marked following ovariectomy. In addition, ovariectomy caused the down-regulation of aortic Ca2+-dependent constitutive nitric oxide synthase (assessed by the citrulline assay). The down-regulation of the Ca2+-dependent constitutive nitric oxide synthase and augmentation of vasopressin-induced blood pressure responses were prevented by the therapy (1 month, p.o.) with the selective oestrogen receptor modulator, raloxifene (0.3-1.0 mg kg(-1) day(-1)), or with 17 beta -oestradiol (0.3 mg kg(-1) day(-1)) in ovariectomized rats. Thus, oestrogen deficiency down-regulates vascular constitutive nitric oxide synthase, which appears to be involved in the increased sensitivity of the vasculature to vasopressin, since both effects can be reversed by the exogenous administration of the natural oestrogen 17 beta -oestradiol or the selective oestrogen-receptor modulator raloxifene. (C) 2000 Elsevier Science B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available